Navigation Links
Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear
Date:1/31/2008

SEATTLE, Jan. 31 /PRNewswire/ -- Use of vitamin and mineral supplements among cancer survivors is widespread, despite inconclusive evidence that such use is beneficial, according to a comprehensive review of scientific literature conducted by researchers at Fred Hutchinson Cancer Research Center and published Feb. 1 in the Journal of Clinical Oncology.

"Can vitamin and herbal supplements reduce the adverse effects of cancer treatment, decrease the risk of cancer recurrence or improve a patient's chances of survival? We don't really know. Research into these matters has been minimal," said senior author Cornelia (Neli) Ulrich, Ph.D., an associate member of the Hutchinson Center's Public Health Sciences Division. "While supplement use may be beneficial for some patients, such as those who cannot eat a balanced diet, research suggests that certain supplements may actually interfere with treatment or even accelerate cancer growth," she said.

In reviewing 32 studies conducted between 1999 and 2006, Ulrich and co-author Christine Velicer, Ph.D., formerly a postdoctoral fellow at the Hutchinson Center (now an epidemiologist at Merck Research Laboratory in North Wales, Pa.), found that many of the nation's 10 million adult cancer survivors use nutritional supplements.

They found 64 percent to 81 percent of cancer survivors overall reported using vitamins or minerals (excluding multivitamins), whereas in the general population only 50 percent of adults reported taking dietary supplements.

Survivors of breast cancer reported the highest use (75 percent to 87 percent), whereas prostate-cancer survivors reported the least (26 percent to 35 percent). Factors associated with the highest level of supplement use overall included a higher level of education and being female.

The researchers also found that many people initiate the use of vitamins and supplements after cancer diagnosis; between 14 percent and 32 percent start taking them afte
'/>"/>

SOURCE Fred Hutchinson Cancer Research Center
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
2. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
3. Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says
4. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
5. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
6. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
7. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
8. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
9. Study Examines Media Preferences of Life Scientists in Applied Markets
10. Triage study challenges notions of emergency medical response to disaster
11. Federally-Funded Study Shows More Women Can Avoid Hysterectomy for Common Problem
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud to announce ... gluten in foods, has been accepted by AOAC International as Official First Action ... Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific monoclonal antibody ...
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, a designer ... & Marketing Director. , With more than 25 years of experience in ... Tronics’ business development activities worldwide. He brings to the company his strong expertise ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against the ... $697 million compared to $701 million in the second ... changes in foreign currency exchange rates decreased sales by ... By business unit, organic sales growth was 6% in ... , Reported diluted EPS was $0.98 compared to ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... , CHICAGO, July 31 ... that it received a complete response letter today from the ... Application (NDA) for Restanza(TM) (cethromycin) for the outpatient treatment of ... letter, the FDA indicated that they cannot approve the application ...
... , , , ... (Nasdaq: CEPH ) announced today that Craig C. Phillips has ... Unit. In this role, Phillips will have responsibility for managing all aspects ... , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090731/PH54744 ...
... Ueno, Ltd. announced on July 29 after discussing its R&D policy ... day and determined the R&D items as follows. , , ... ophthalmologic & dermatological fields that are its priority and exclusive areas, ... 1. Development code UF-021 (eye diseases) , , ...
Cached Biology Technology:Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia 2Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia 3Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia 4Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia 5Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit 2Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit 3Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit 4R-Tech Ueno Notifies R&D Items 2R-Tech Ueno Notifies R&D Items 3
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. ... of human interface solutions, today announced a ... first fully hardware encapsulated fingerprint sensor and ... technology is literally off the grid, isolating ... matching within the fingerprint sensor to provide ...
(Date:7/8/2015)... The consumer products industry for innovative ... products such as wearables, smart wallets & other smart technology ... devices continues to rapidly grow.  Biometrics & Wearable Device Companies ... Google Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... (NASDAQ: GPRO ) and Baidu Inc. (NASDAQ: BIDU ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6
... new twist on an old idea, two Clemson University environmental ... cut heating and cooling costs and reduce carbon emissions. ... from the U.S. Department of Defense to create a Subsurface ... a model for energy efficiency. Five military bases are ...
... Cornell University researchers recently stretched individual molecules and ... can be used as powerful new tools for nanoscale ... 11 issue of the journal Science, probes ... important when shrinking electronics to their ultimate small size ...
... In what has been hailed as a breakthrough, scientists ... College have outlined the molecular mechanism of membrane transport. ... to transport substances across the cell membrane in order ... synaptic gap from one neuron to another. Because ...
Cached Biology News:Clemson engineers to create model underground energy-storage facility 2Clemson engineers to create model underground energy-storage facility 3Stretching molecules yields new understanding of electricity 2Helping the brain's messengers get from A to B 2Helping the brain's messengers get from A to B 3
Monoclonal antibodies conjugated with rhodamine...
... Both compact and lightweight, the Moticam ... microscope through the eyepiece, eyetube, or trinocular ... easy to use Plug-and-Play Images 2.0ML software ... Image manipulation tools to maximize resolution for ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
... BSA-Free Stabilizer is a bovine protein-free ... It is an aqueous solution that ... MOPS buffer (3-(N-Morpholino) propanesulfonic acid), pH ... combination of 0.02% methylisothiazolone and 0.02% ...
Biology Products: